Insurance and reinsurance broker BMS Group has announced the appointment of Manoela Barbi Kukli as the new Head of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corp. (XOM), ...

Through the partnership, Fulmer Insurance Group agents will gain access to Integrity’s platform of technology solutions, ...

Reinsurance brokerage BMS Group has concluded the acquisition of Spanish insurance broker Rasher following the receipt of regulatory approvals. The deal, whose financial terms remain undisclosed ...

Zack Sigel is a writer and editor based in New York City. He has been managing editor at Policygenius and M1 Finance, where he led teams specialized in writing about business and finance, and he ...

After obtaining regulatory approvals, BMS Group has now completed its acquisition of Spanish insurance broker Rasher, which specialises in surety, credit, finance and risk management solutions for ...

BMS Group has completed its acquisition of Rasher, a specialist insurance broker focused on surety, credit, finance, and risk management solutions for corporate clients. The transaction, which ...

BMS managing director (MD) and head of international operations David Battman is leaving the brokerage, this publication can reveal. Based in London, the executive joined BMS nine years ago to ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement. Bristol Myers Squibb is stepping in to buy its Abecma partner 2seventy bio ...

BMS and 2seventy bio first teamed up in 2021. Credit: Moyo Studio via Getty Images. Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at ...